Repinotan, A 5-HT1A Agonist, in the Treatment of Acute Ischemic Stroke

Author(s): Helmi L. Lutsep

Journal Name: Current Drug Targets - CNS & Neurological Disorders
Continued as CNS & Neurological Disorders - Drug Targets

Volume 4 , Issue 2 , 2005


Serotonin agonists can reduce glutamate-induced excitotoxicity in cerebral ischemia. The potent 5- HT1A agonist BAY x 3702, or repinotan, has reduced cortical infarct volume in pre-clinical models even when given 5 hours after injury. Early clinical trials showed that the drug was safe, and displayed primarily serotonergic side effects such as nausea and vomiting. A phase IIb trial in moderate to moderately severe strokes completed enrollment in June 2004.

Keywords: Infarct, ischemia, acute stroke treatment, neuroprotection, neuroprotectant, repinotan

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Published on: 01 March, 2012
Page: [119 - 120]
Pages: 2
DOI: 10.2174/1568007053544165
Price: $65

Article Metrics

PDF: 2